newsfilter
← Latest News
GlobeNewswire·

ASH 2025 | Ascentage Pharma Presents First Dataset from Phase III POLARIS-1 Study of Olverembatinib in Newly Diagnosed Ph+ ALL Shows a Best MRD-Negativity CR Rate Exceeding 60%

  • Ascentage Pharma presented initial Phase III POLARIS-1 study data for Olverembatinib combined with low-intensity chemotherapy in newly diagnosed Ph+ ALL at the 2025 ASH Annual Meeting.
  • By the end of three induction cycles, the best MRD negativity rate was 66.0% and the MRD-negative complete response rate was 64.2%.
  • High-risk patients with the IKZF1 plus genotype demonstrated a 90% molecular response rate.
  • Among 53 evaluable patients, 94.3% achieved a complete response or complete response with incomplete hematologic recovery.
  • The treatment regimen showed a favorable safety profile with common grade 3 or higher adverse events including neutropenia (63.6%), thrombocytopenia (56.4%), and leukopenia (54.5%).
  • Olverembatinib is the first third-generation BCR-ABL inhibitor approved in China for specific CML indications covered by the NRDL.
  • The POLARIS-1 study received clearance from both the U.S. FDA and the European Medicines Agency.
  • Ascentage Pharma has an exclusive option agreement with Takeda for global development and commercialization rights outside mainland China, Hong Kong, Macau, and Taiwan.
  • The company is conducting multiple global Phase III trials for Olverembatinib in CML, Ph+ ALL, and SDH-deficient GIST.